Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIL204-SL plus chemotherapy vs chemotherapy in locally advanced pancreatic cancer
2025-525157-39-00Phase 3Authorised
- Sponsor
- Silexion Therapeutics
- Start
- Jun 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) comparing SIL204-SL + standard-of-care chemotherapy with Standard-of-care chemotherapy alone (2 arms). Primary endpoints: Overall survival (primary, Segments 2 & 3), Safety and DLT (Segment 1) and 4 more. Planned start Jun 2026; status: authorised.
02
Drugs
SIL204-SL
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2025-525157-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525157-39-00.